Clinical Trials

Accrual Status
Limit to SWOG Trials

1040 Results

View
Open
Phase
Accrual
35%
SWOG Clinical Trial Number
S1900G

A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900G will open to accrual April 3, 2023, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
04-03-2023
ClinicalTrials.gov Registry Number
05642572
Open
Phase
Accrual
66%
SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Status Notes
This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
03-16-2023
ClinicalTrials.gov Registry Number
05642611
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Status Notes
S2302 will permanently closed to accrual effective December 20, 2024, at 12:00 p.m. Pacific Time.
Research Committee(s)
Lung Cancer
Activated
03-06-2023
Closed
12-20-2024
ClinicalTrials.gov Registry Number
05633602
Open
Phase
Accrual
97%
SWOG Clinical Trial Number
EAY191-S3

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors
Status Notes
This study is open to participant enrollment effective 12pm PT on 3/6/2023.
Research Committee(s)
comboMATCH
Immunomolecular Therapeutics
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05554380
Open
Phase
Accrual
45%
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Research Committee(s)
Lymphoma
Activated
02-23-2023
ClinicalTrials.gov Registry Number
05633615
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Status Notes
This study is permanently closed to participant accrual, effective January 15, 2025, at 12:00 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
01-17-2023
Open
Phase
Accrual
33%
SWOG Clinical Trial Number
S2101

Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
Status Notes
Stage II Activation: This study will be reopen to Stage II accrual to both the Melanoma and HNSCC cohorts effective May 1st, 2025, at 3:00 PM ET / 12:00 PM PT.
Research Committee(s)
iMATCH
Head and Neck Cancer
Melanoma
Early Therapeutics & Rare Cancers
Immunomolecular Therapeutics
Activated
10-14-2022
ClinicalTrials.gov Registry Number
NCT 05136196
Open
Phase
Accrual
18%
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Status Notes
Active effective 09/19/2022
Research Committee(s)
Genitourinary Cancer
Activated
09-19-2022
ClinicalTrials.gov Registry Number
NCT05411081
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S2108CD

A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
Status Notes
This study will be permanently closed to new patient accrual, effective November 22, 2024, at 3:00 p.m. Eastern Time.
Research Committee(s)
Cancer Care Delivery
Activated
08-22-2022
ClinicalTrials.gov Registry Number
NCT # 05455606
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status Notes
Closed 6/27/2023
Research Committee(s)
LungMAP
Activated
07-25-2022
Closed
06-27-2023
ClinicalTrials.gov Registry Number
05364645
Closed
Phase
Accrual
17%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status Notes
S1800D is permanently closed to accrual, effective March 10, 2023. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Closed
03-10-2023
Open
Phase
Accrual
69%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
Accrual
54%
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S2011

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Status Notes
The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
Closed
11-15-2023
ClinicalTrials.gov Registry Number
04871529
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1934

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
S1934 is permanently closed effective 3/1/2023.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
Closed
03-01-2023
ClinicalTrials.gov Registry Number
04989283
Open
Phase
Accrual
65%
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
Effective on 11/15/24 with Revision #6, Cohort 1 is permanently closed to accrual and Cohort 2 is open to enrollment.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
This study will be permanently closed to new patient and caregiver accrual, effective December 16, 2024, at 12:00 p.m. Pacific Time.
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
24%
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Status Notes
Re-Activation - Effective (2/15/2024)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
Effective December 27, 2024 at 12:00 p.m. Pacific Time, sub-study S1900E will be permanently closed to accrual as it has met its protocol-specified accrual goal.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021
Closed
12-27-2024
Open
Phase
Accrual
32%
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time

Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275